Elsevier

Biochemical Pharmacology

Volume 54, Issue 11, 1 December 1997, Pages 1173-1179
Biochemical Pharmacology

Commentary
EB 1089, a novel vitamin D Analog with strong antiproliferative and differentiation-inducing effects on target cells

https://doi.org/10.1016/S0006-2952(97)00181-0Get rights and content

Abstract

The physiologically active form of vitamin D, 1α,25-dihydroxyvitamin D3, plays an important role not only in the establishment and maintenance of calcium metabolism, but also in regulating cell growth and differentiation. As the clinical usefulness of 1α,25-dihydroxyvitamin D3 is limited by its tendency to cause hypercalcemia, new analogs with a better therapeutic profile have been synthesized. One of these new synthetic vitamin D analogs is EB 1089, which is characterized by an altered side chain structure featuring 26,27-dimethyl groups and two double bonds. This analog has been shown to be more potent than 1,25-dihydroxyvitamin D3 in inhibiting proliferation, stimulating differentiation, and inducing apoptosis in a number of different cell types, including cancer cells. Despite being more potent than 1α,25-dihydroxyvitamin D3 with respect to its cell regulatory effects, EB 1089 displays weaker calcemic side-effects. These characteristics make EB 1089 a potentially useful compound for the treatment of a diversity of clinical disorders, including cancer and metabolic bone diseases. A promising phase I study with EB 1089 in patients with advanced breast and colon cancer has already been carried out, and more clinical trials evaluating the clinical effectiveness of EB 1089 in other types of cancer are in progress.

References (58)

  • SY James et al.

    Effects of 1,25-dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells

    J Steroid Biochem Mol Biol

    (1996)
  • C Baudet et al.

    Cytotoxic effects of 1α,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line

    Cancer Lett

    (1996)
  • T Vink-van Wijngaarden et al.

    Inhibition of insulin-like growth factor-1-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB 1089

    Eur J Cancer

    (1996)
  • MM Medhora et al.

    1α,25-Dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin αvβ3

    J Biol Chem

    (1993)
  • PM Petkovich et al.

    1,25-Dihydroxyvitamin D3 increases epidermal growth factor receptors and transforming growth factor-β-like activity in a bone-derived cell line

    J Biol Chem

    (1987)
  • SS Hannah et al.

    1α,25(OH)2 Vitamin D3-regulated expression of the eukaryotic genome

    Nutr Rev

    (1994)
  • MF Holick

    Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications

    Bone

    (1995)
  • H Darwish et al.

    Vitamin D regulated gene expression

    Crit Rev Eukaryot Gene Expr

    (1993)
  • WE Duncan et al.

    Estrogen regulation of the nuclear 1,25-dihydroxyvitamin D3 receptor in rat liver and kidney

    Endocrinology

    (1991)
  • C Carlberg

    Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling

    Eur J Biochem

    (1995)
  • S Christakos et al.

    Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3

    Biochem J

    (1996)
  • L Binderup et al.

    The need for new vitamin D analogues: Mechanisms of action and clinical applications

  • KW Colston

    Vitamin D and breast cancer: The therapeutic potential of new vitamin D analogues

    Endocr Relat Cancer

    (1995)
  • S Nayeri et al.

    The anti-proliferative effect of vitamin D3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity

    Oncogene

    (1995)
  • S Roy et al.

    Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase

    J Bone Miner Res

    (1995)
  • A-M Kissmeyer et al.

    Pharmacokinetic studies of vitamin D analogues: Relationship to vitamin D binding protein (DBP)

    Endocrine

    (1995)
  • AW Norman et al.

    Selective biological response by target organs (intestine, kidney and bone) to 1,25-dihydroxyvitamin D, and two analogues

    Cancer Res

    (1993)
  • R Bouillon et al.

    Structure-function relationships in the vitamin D endocrine system

    Endocr Rev

    (1995)
  • C Mørk Hansen et al.

    The antiproliferative and differentiation-inducing effects of vitamin D analogues are not determined by the binding affinity for the vitamin D receptor alone

  • Cited by (81)

    • Vitamin D Signaling Modulators in Cancer Therapy

      2016, Vitamins and Hormones
      Citation Excerpt :

      MART-10 shows more potent than 1,25D3 in inhibiting cell proliferation in prostate cancer and breast cancer (Chiang et al., 2014, 2012; Flanagan et al., 2009). Seocalcitol (EB1089) and 20-epi-1,25D3 with modifications of the side chain of 1,25D3 are degraded more slowly than 1,25D3, leading to more prolong exposure of these analogs to the tissues (Hansen & Maenpaa, 1997; Kissmeyer et al., 1997; Shankar et al., 1997; Zella, Meyer, Nerenz, & Pike, 2009). Lexicalcitol (KH1060) is more effective in stabilizing VDR against degradation than 1,25D3 (Jaaskelainen, Ryhanen, Mahonen, DeLuca, & Maenpaa, 2000; van den Bemd, Pols, Birkenhager, & van Leeuwen, 1996).

    • A new insight into the role of rat cytochrome P450 24A1 in metabolism of selective analogs of 1α,25-dihydroxyvitamin D<inf>3</inf>

      2011, Archives of Biochemistry and Biophysics
      Citation Excerpt :

      All these analogs were found to have remarkable biological properties when compared to 1, for some of them sufficiently promising to enter clinical drug development [22–25]. In particular, analog 6 (EB1089) has been extensively studied including its metabolism [26–30]. It was shown that 6 was metabolized into two metabolites identified as C26-hydroxy-6 and C26a-hydroxy-6 and the enzyme responsible for its metabolism was not CYP24A1 [27].

    View all citing articles on Scopus
    View full text